Literature DB >> 23138280

Calamitous HCV trial casts shadow over nucleoside drugs.

Cormac Sheridan.   

Abstract

Mesh：

Substances：

Year:  2012        PMID： 23138280     DOI： 10.1038/nbt1112-1015

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  2 in total

1.  Metabolic activation of the anti-hepatitis C virus nucleotide prodrug PSI-352938.

Authors:  Congrong Niu; Tatiana Tolstykh; Haiying Bao; Yeojin Park; Darius Babusis; Angela M Lam; Shalini Bansal; Jinfa Du; Wonsuk Chang; P Ganapati Reddy; Hai-Ren Zhang; Joseph Woolley; Li-Quan Wang; Piyun B Chao; Adrian S Ray; Michael J Otto; Michael J Sofia; Phillip A Furman; Eisuke Murakami
Journal:  Antimicrob Agents Chemother       Date:  2012-04-23       Impact factor: 5.191

2.  Activity and the metabolic activation pathway of the potent and selective hepatitis C virus pronucleotide inhibitor PSI-353661.

Authors:  Phillip A Furman; Eisuke Murakami; Congrong Niu; Angela M Lam; Christine Espiritu; Shalini Bansal; Haiying Bao; Tatiana Tolstykh; Holly Micolochick Steuer; Meg Keilman; Veronique Zennou; Nigel Bourne; Ronald L Veselenak; Wonsuk Chang; Bruce S Ross; Jinfa Du; Michael J Otto; Michael J Sofia
Journal:  Antiviral Res       Date:  2011-05-12       Impact factor: 5.970
  2 in total
  5 in total

1.  Nucleotide Substrate Specificity of Anti-Hepatitis C Virus Nucleoside Analogs for Human Mitochondrial RNA Polymerase.

Authors:  Maryam Ehteshami; Longhu Zhou; Sheida Amiralaei; Jadd R Shelton; Jong Hyun Cho; Hongwang Zhang; Hao Li; Xiao Lu; Tugba Ozturk; Richard Stanton; Franck Amblard; Tamara R McBrayer; Steven J Coats; Raymond F Schinazi
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

2.  Substrate recognition by norovirus polymerase: microsecond molecular dynamics study.

Authors:  Kamil Maláč; Ivan Barvík
Journal:  J Comput Aided Mol Des       Date:  2013-04-26       Impact factor: 3.686

3.  Biochemical Characterization of the Active Anti-Hepatitis C Virus Metabolites of 2,6-Diaminopurine Ribonucleoside Prodrug Compared to Sofosbuvir and BMS-986094.

Authors:  Maryam Ehteshami; Sijia Tao; Tugba Ozturk; Longhu Zhou; Jong Hyun Cho; Hongwang Zhang; Sheida Amiralaei; Jadd R Shelton; Xiao Lu; Ahmed Khalil; Robert A Domaoal; Richard A Stanton; Justin E Suesserman; Biing Lin; Sam S Lee; Franck Amblard; Tony Whitaker; Steven J Coats; Raymond F Schinazi
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

Review 4.  Chutes and ladders in hepatitis C nucleoside drug development.

Authors:  Steven J Coats; Ethel C Garnier-Amblard; Franck Amblard; Maryam Ehteshami; Sheida Amiralaei; Hongwang Zhang; Longhu Zhou; Sebastien R L Boucle; Xiao Lu; Lavanya Bondada; Jadd R Shelton; Hao Li; Peng Liu; Chengwei Li; Jong Hyun Cho; Satish N Chavre; Shaoman Zhou; Judy Mathew; Raymond F Schinazi
Journal:  Antiviral Res       Date:  2013-11-23       Impact factor: 5.970

Review 5.  Novel drugs in the management of difficult-to-treat hepatitis C genotypes.

Authors:  Emily J Cartwright; Lesley Miller
Journal:  Hepat Med       Date:  2013-08-20
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.